Cargando…

Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension

AIMS: There are few proven strategies to enhance physical activity and cardiometabolic profiles in patients with type 2 diabetes and hypertension. We examined the effects of physician‐delivered step count prescriptions and monitoring. METHODS: Participants randomized to the active arm were provided...

Descripción completa

Detalles Bibliográficos
Autores principales: Dasgupta, Kaberi, Rosenberg, Ellen, Joseph, Lawrence, Cooke, Alexandra B., Trudeau, Luc, Bacon, Simon L., Chan, Deborah, Sherman, Mark, Rabasa‐Lhoret, Rémi, Daskalopoulou, Stella S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412851/
https://www.ncbi.nlm.nih.gov/pubmed/28074635
http://dx.doi.org/10.1111/dom.12874
_version_ 1783233087707021312
author Dasgupta, Kaberi
Rosenberg, Ellen
Joseph, Lawrence
Cooke, Alexandra B.
Trudeau, Luc
Bacon, Simon L.
Chan, Deborah
Sherman, Mark
Rabasa‐Lhoret, Rémi
Daskalopoulou, Stella S.
author_facet Dasgupta, Kaberi
Rosenberg, Ellen
Joseph, Lawrence
Cooke, Alexandra B.
Trudeau, Luc
Bacon, Simon L.
Chan, Deborah
Sherman, Mark
Rabasa‐Lhoret, Rémi
Daskalopoulou, Stella S.
author_sort Dasgupta, Kaberi
collection PubMed
description AIMS: There are few proven strategies to enhance physical activity and cardiometabolic profiles in patients with type 2 diabetes and hypertension. We examined the effects of physician‐delivered step count prescriptions and monitoring. METHODS: Participants randomized to the active arm were provided with pedometers and they recorded step counts. Over a 1‐year period, their physicians reviewed their records and provided a written step count prescription at each clinic visit. The overall goal was a 3000 steps/day increase over 1 year (individualized rate of increase). Control arm participants were advised to engage in physical activity 30 to 60 min/day. We evaluated effects on step counts, carotid femoral pulse wave velocity (cfPWV, primary) and other cardiometabolic indicators including haemoglobin A1c in diabetes (henceforth abbreviated as A1c) and Homeostasis Model Assessment‐Insulin Resistance (HOMA‐IR) in participants not receiving insulin therapy. RESULTS: A total of 79% completed final evaluations (275/347; mean age, 60 years; SD, 11). Over 66% of participants had type 2 diabetes and over 90% had hypertension. There was a net 20% increase in steps/day in active vs control arm participants (1190; 95% CI, 550‐1840). Changes in cfPWV were inconclusive; active vs control arm participants with type 2 diabetes experienced a decrease in A1c (−0.38%; 95% CI, −0.69 to −0.06). HOMA‐IR also declined in the active arm vs the control arm (ie, assessed in all participants not treated with insulin; −0.96; 95% CI, −1.72 to −0.21). CONCLUSIONS: A simple physician‐delivered step count prescription strategy incorporated into routine clinical practice led to a net 20% increase in step counts; however, this was below the 3000 steps/day targeted increment. While conclusive effects on cfPWV were not observed, there were improvements in both A1c and insulin sensitivity. Future studies will evaluate an amplified intervention to increase impact.
format Online
Article
Text
id pubmed-5412851
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-54128512017-05-15 Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension Dasgupta, Kaberi Rosenberg, Ellen Joseph, Lawrence Cooke, Alexandra B. Trudeau, Luc Bacon, Simon L. Chan, Deborah Sherman, Mark Rabasa‐Lhoret, Rémi Daskalopoulou, Stella S. Diabetes Obes Metab Original Articles AIMS: There are few proven strategies to enhance physical activity and cardiometabolic profiles in patients with type 2 diabetes and hypertension. We examined the effects of physician‐delivered step count prescriptions and monitoring. METHODS: Participants randomized to the active arm were provided with pedometers and they recorded step counts. Over a 1‐year period, their physicians reviewed their records and provided a written step count prescription at each clinic visit. The overall goal was a 3000 steps/day increase over 1 year (individualized rate of increase). Control arm participants were advised to engage in physical activity 30 to 60 min/day. We evaluated effects on step counts, carotid femoral pulse wave velocity (cfPWV, primary) and other cardiometabolic indicators including haemoglobin A1c in diabetes (henceforth abbreviated as A1c) and Homeostasis Model Assessment‐Insulin Resistance (HOMA‐IR) in participants not receiving insulin therapy. RESULTS: A total of 79% completed final evaluations (275/347; mean age, 60 years; SD, 11). Over 66% of participants had type 2 diabetes and over 90% had hypertension. There was a net 20% increase in steps/day in active vs control arm participants (1190; 95% CI, 550‐1840). Changes in cfPWV were inconclusive; active vs control arm participants with type 2 diabetes experienced a decrease in A1c (−0.38%; 95% CI, −0.69 to −0.06). HOMA‐IR also declined in the active arm vs the control arm (ie, assessed in all participants not treated with insulin; −0.96; 95% CI, −1.72 to −0.21). CONCLUSIONS: A simple physician‐delivered step count prescription strategy incorporated into routine clinical practice led to a net 20% increase in step counts; however, this was below the 3000 steps/day targeted increment. While conclusive effects on cfPWV were not observed, there were improvements in both A1c and insulin sensitivity. Future studies will evaluate an amplified intervention to increase impact. Blackwell Publishing Ltd 2017-02-22 2017-05 /pmc/articles/PMC5412851/ /pubmed/28074635 http://dx.doi.org/10.1111/dom.12874 Text en © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Dasgupta, Kaberi
Rosenberg, Ellen
Joseph, Lawrence
Cooke, Alexandra B.
Trudeau, Luc
Bacon, Simon L.
Chan, Deborah
Sherman, Mark
Rabasa‐Lhoret, Rémi
Daskalopoulou, Stella S.
Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension
title Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension
title_full Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension
title_fullStr Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension
title_full_unstemmed Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension
title_short Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension
title_sort physician step prescription and monitoring to improve arterial health (smarter): a randomized controlled trial in patients with type 2 diabetes and hypertension
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412851/
https://www.ncbi.nlm.nih.gov/pubmed/28074635
http://dx.doi.org/10.1111/dom.12874
work_keys_str_mv AT dasguptakaberi physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT rosenbergellen physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT josephlawrence physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT cookealexandrab physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT trudeauluc physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT baconsimonl physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT chandeborah physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT shermanmark physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT rabasalhoretremi physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT daskalopouloustellas physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension
AT physicianstepprescriptionandmonitoringtoimprovearterialhealthsmarterarandomizedcontrolledtrialinpatientswithtype2diabetesandhypertension